Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VolitionRX Ltd VNRX

Healthcare Medical Instruments & Supplies
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.


NYSEAM:VNRX - Post by User

VolitionRX Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(39)
•••
Post by tanninon Jan 02, 2024 4:16pm
130 Views
Post# 35807712

Great news.....

Great news.....
  •  
  •  
Copied from Dow Jones News Wires.........

By Josh Beckerman

VolitionRx shares rose 35% Tuesday after the company said it received $13 million in milestone payments from Heska in connection with a March 2022 licensing agreement.

Epigenetics company VolitionRx said in a securities filing that the payments arose from the successful assay transfer of its Nu.Q Vet Cancer Test onto Heska's Element i+ Immunodiagnostic Analyzer veterinary diagnostics platform. Mars bought Heska in June.

To keep, the few of us who might be watching this site for news, updated.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities